N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline
Also known as: ES-Ile-Pro-OPr, Eurystatin A, N-(Epoxysuccinyl)-Ile-Pro propyl ester, POPHA
Source N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline (also known as POPHA or Compound Z-Pro-Prolinal analogue in some literature, most commonly referenced as the prolyl endopeptidase inhibitor Eurystatin A or a close structural analogue) is a naturally-derived or synthetic epoxide dipeptide that potently and irreversibly inhibits prolyl oligopeptidase. It has been used extensively as a research tool to study the role of POP in neuropeptide metabolism, cognition, and neurological disorders. No approved clinical indication exists; it is used primarily in in vitro and animal studies.
Mechanism of Action
Irreversible inhibition of prolyl endopeptidase (prolyl oligopeptidase, POP/PREP) via covalent modification of the active-site serine residue by the epoxide electrophile; reduces cleavage of proline-containing neuropeptides such as substance P, vasopressin, and thyrotropin-releasing hormone
Routes of Administration
Goals & Uses
- Cognitive/memory researchNeuroscience ResearchModerate
- Anti-amnesic investigationInvestigational CNSLow
- Prolyl oligopeptidase inhibitionEnzyme Inhibition / Research ToolHigh
- Neuropeptide metabolism modulationNeuropharmacologyModerate
Contraindications
- Human therapeutic useRegulatory/safetyHigh
Adverse Effects
- Non-selective protease inhibition at high concentrationsOff Target EffectUnknown
- Irreversible enzyme inactivationPharmacodynamicUnknown
Drug Interactions
- Other serine protease inhibitorsLow
Population Constraints
- HumansRegulatory / SafetyAbsolute
- Pregnant animalsReproductiveRelative
Regulatory Status
- European UnionUnapprovedResearch compound only; not authorized by EMA
- United StatesUnapprovedResearch compound only; no FDA approval or IND on record
- United KingdomUnapprovedResearch compound only; not authorized by MHRA
Not approved for human therapeutic use in any jurisdiction. Used as a pharmacological research tool. No IND or clinical trial registration identified for this specific compound.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline?
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline (also known as POPHA or Compound Z-Pro-Prolinal analogue in some literature, most commonly referenced as the prolyl endopeptidase inhibitor Eurystatin A or a close structural analogue) is a naturally-derived or synthetic epoxide dipeptide that potently and irreversibly inhibits prolyl oligopeptidase. It has been used extensively as a research tool to study the role of POP in neuropeptide metabolism, cognition, and neurological disorders. No approved clinical indication exists; it is used primarily in in vitro and animal studies.
What is N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline used for?
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline is educationally associated with: Cognitive/memory research, Anti-amnesic investigation, Prolyl oligopeptidase inhibition, Neuropeptide metabolism modulation. Educational only — not medical advice.
How is N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline administered?
Recorded routes of administration: In Vitro, Intraperitoneal, Intravenous.
What are the potential side effects of N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline?
Reported adverse effects include: Non-selective protease inhibition at high concentrations, Irreversible enzyme inactivation. This list is not exhaustive — consult a qualified clinician.
Who should avoid N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline?
Recorded contraindications: Human therapeutic use. Consult a qualified clinician before use.